KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Work In Process (2018 - 2025)

Rigel Pharmaceuticals (RIGL) has 8 years of Work In Process data on record, last reported at $5.5 million in Q3 2025.

  • For Q3 2025, Work In Process rose 202.98% year-over-year to $5.5 million; the TTM value through Sep 2025 reached $5.5 million, up 202.98%, while the annual FY2024 figure was $1.2 million, 34.65% down from the prior year.
  • Work In Process reached $5.5 million in Q3 2025 per RIGL's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Work In Process topped out at $6.0 million in Q2 2024 and bottomed at $162000.0 in Q4 2021.
  • Average Work In Process over 5 years is $2.0 million, with a median of $1.5 million recorded in 2022.
  • Peak YoY movement for Work In Process: tumbled 86.38% in 2021, then surged 1541.36% in 2022.
  • A 5-year view of Work In Process shows it stood at $162000.0 in 2021, then soared by 1541.36% to $2.7 million in 2022, then decreased by 29.45% to $1.9 million in 2023, then crashed by 34.65% to $1.2 million in 2024, then surged by 347.55% to $5.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $5.5 million in Q3 2025, $2.0 million in Q2 2025, and $1.1 million in Q1 2025.